 |
| CEYY Continues Aggressive Growth Plan BMIX Interview is a Gem |
|
 Hot Stock to Watch
|
Company: Brazil Minerals Inc. (OTCQB: BMIX)
|
End of Day:
Price: 0.077
Change (%): - 0.003 (3.75)
Volume: 98,741 |
 |
A New Audio Interview With Marc Fogassa, Chairman and CEO of BMIX, is Now at SmallCapVoice.com
AUSTIN, Texas, Dec. 16, 2013 (GLOBE NEWSWIRE) - SmallCapVoice.com, Inc. (SCV) announced today that a new audio interview with Brazil Minerals, Inc. (OTCQB:BMIX) (the “Company” or “BMIX”), is a diversified mining company and a producer of diamonds and gold at its Mineração Duas Barras Ltda. (“Duas Barras”) subsidiary located in the state of Minas Gerais in Brazil, is now available. The interview can be heard at http://smallcapvoice.com/blog/12-12-13-smallcapvoice-interview-with-brazil-minerals-bmix
Marc Fogassa, chairman and CEO of BMIX, called into SmallCapVoice.com to update the listening audience on the business model, markets, management team, goals for Brazil Minerals, Inc., and much more.
Continue Reading
|
Company: Fresh Start Private Management Inc. (OTCQB: CEYY)
|
End of Day:
Price: 0.1124
Change (%): - 0.0076 (6.33)
Volume: 31,605 |
 |
Fresh Start Private Management, Inc. Completes Connecticut Licensing Agreement
LOS ANGELES, CA-(Marketwired - Dec 16, 2013) - Fresh Start Private Management Inc. (OTCQB: CEYY), a leader in alcohol treatment and rehabilitation programs, announces the completion of the licensing agreement with JPL, LLC granting them exclusive license and distribution rights of its alcohol treatment program in Connecticut. Under the terms of the executed agreement, JPL, LLC is paying Fresh Start Private an upfront licensing fee and running royalties on program sales in Connecticut for the agreement term. The clinic will operate under the name Start Fresh Recovery and plans to be located around the New Haven area.
This licensing agreement is yet another validation for the treatment program as well as for the Fresh Start Private business model. The company continues to execute on its aggressive growth strategy as shown by the recently announced openings in Northern California, Nebraska, Arizona, and the continued negotiations for the country of Mexico. The Northern California clinic has reported a tremendous amount of activity in its first week.
Continue Reading
|
 Yesterday's Top Performer
|
Company: Advanced Medical Isotope Corp. (OTCQB: ADMD)
|
End of Day:
Price: 0.07
Change (%): + 0.0097 (16.09)
Volume: 426,943 |
 |
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (OTCBB:ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel™. AMIC intends to file FDA premarket notifications for two related Yttrium-90 brachytherapy products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans.
Company Information Sheet |
Other Small Cap News
|
Company: Nuvilex, Inc. (OTCQB: NVLX)
|
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage clinical trials in advanced, inoperable pancreatic cancer that is. In an editorial that accompanied the findings of an epidemiological study of patients with pancreatic cancer published in the November 20 issue of the Journal of the National Cancer Institute (JNCI), treatments using the drug gemcitabine for the disease were put on notice and treatments not using gemcitabine alone or in combination with another drug as a treatment are being sought. Nuvilex has just such a treatment ready for late-phase clinical trials.
Continue Reading
|
Company: Athersys, Inc. (Nasdaq: ATHX)
|
Athersys (ATHX) in Focus: Stock Moves 6.8% Higher
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up 13.4% over the past one month time frame.
The company has seen a mixed track record when it comes to estimate revisions, of one increase and one decrease over the past one month, while the Zacks Consensus Estimate has remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Continue Reading |
Market News
|
By Ricardo Alonso-Zaldivar and Jennifer Agiesta: Associated Press
|
AP-GfK poll: Health law seen as eroding coverage
AP-GfK poll: Obama's health care problem goes beyond website as many say coverage is eroding
WASHINGTON (AP) -- Americans who already have health insurance are blaming President Barack Obama's health care overhaul for their rising premiums and deductibles, and overall 3 in 4 say the rollout of coverage for the uninsured has gone poorly.
An Associated Press-GfK poll finds that health care remains politically charged going into next year's congressional elections. Keeping the refurbished HealthCare.gov website running smoothly is just one of Obama's challenges, maybe not the biggest.
Continue Reading
|
By Chuck Jaffe: MarketWatch
|
9 dumbest mutual fund moves of 2013
Chuck Jaffe hands the industry his annual Lump of Coal awards
Investors overlook a lot of mistakes mutual funds make, so long as those errors don’t show up in their account statement.
It’s the 18th annual Lump of Coal Awards, my two-part holiday tradition of easing Santa’s burden by singling out the bad boys and girls of the fund industry who deserve a lousy lump of lignite in their Christmas stockings this year.
If these booby prizes were based entirely on performance, there would be little to write about in 2013, with the stock market up about 30% year-to-date.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
